DEMO

Log In | Sign Up



Bristol-Myers Squibb

Selected Articles

2025-08-14
ETF Daily News
InfuSystem (NYSE:INFU) versus Perspective Therapeutics (NYSE:CATX) Head to Head Comparison
2025-08-13
Plos.org
Mechanistic modeling suggests stroma-targeting antibody-drug conjugates as an alternative to cancer-targeting in cases of heterogeneous target exspression
2025-08-13
GlobeNewswire
Cytokines Market Forecast Report 2025-2030 | Revenues to Hit $145.25 Billion by 2030 | Detailed Insights by Type, Production, Formulation, Application, Country and Company
2025-08-12
GlobeNewswire
Erectile Dysfunction Devices Market Set to Surge at a CAGR of ~8% by 2032 with Rising Global Demand and Technological Advancements | DelveInsight
2025-08-12
GlobeNewswire
Cannabinoid Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
2025-08-12
MedCity News
BioNTech To Pay CureVac, GSK $740M Plus Royalties To Settle mRNA Patent Disputes
2025-08-12
GlobeNewswire
X4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board Leadership
2025-08-12
GlobeNewswire
Viral Sensitizers Global Strategic Research Report 2025-2030 | Expansion of mRNA and Viral Vector Platforms Strengthens the Case for Optimized Viral Sensitizers
2025-08-12
GlobeNewswire
Vitiligo Treatment Strategic Market Research Report 2025-2030 | Increased Psychological and Social Impact of Vitiligo Drives Demand for More Effective Therapies
2025-08-12
ETF Daily News
Perspective Therapeutics (NYSE:CATX) and T2 Biosystems (NASDAQ:TTOO) Financial Comparison

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey. US1101221083 www.bms.com